Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
Type:
Grant
Filed:
September 2, 2020
Date of Patent:
December 19, 2023
Assignee:
Grünenthal GmbH
Inventors:
Johannes Bartholomäus, Heinrich Kugelmann, Elisabeth Arkenau-Maric
Abstract: The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
November 14, 2022
Publication date:
September 28, 2023
Applicant:
Grünenthal GmbH
Inventors:
Sven KUEHNERT, Rene KOENIGS, Achim KLESS, Anita WEGERT, Ingo KONETZKI, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
Abstract: The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.
Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
January 13, 2020
Publication date:
March 24, 2022
Applicant:
GRÜNENTHAL GMBH
Inventors:
Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Daniela FRIEBE, Stephanie HENNEN, Philipp BARBIE
Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
Type:
Grant
Filed:
September 6, 2016
Date of Patent:
January 18, 2022
Assignee:
GRÜNENTHAL GMBH
Inventors:
Elisabeth Arkenau-Marić, Johannes Bartholomäus
Abstract: A hitherto unknown crystalline form of (?)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
Type:
Application
Filed:
March 8, 2021
Publication date:
August 26, 2021
Applicant:
Grünenthal GmbH
Inventors:
Andreas FISCHER, Helmut BUSCHMANN, Michael GRUSS, Dagmar LISCHKE
Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
March 1, 2021
Publication date:
July 15, 2021
Applicant:
Grünenthal GmbH
Inventors:
Sven Kuehnert, Rene Michael Koenigs, Florian Jakob, Achim Kless, Anita Wegert, Paul Ratcliffe, Ruth Jostock, Thomas Koch, Klaus Linz, Wolfgang Schroeder
Abstract: The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
March 1, 2021
Publication date:
June 24, 2021
Applicant:
Grünenthal GmbH
Inventors:
Sven KUEHNERT, Rene KOENIGS, Achim KLESS, Anita WEGERT, Ingo KONETZKI, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
Abstract: The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
March 1, 2021
Publication date:
June 17, 2021
Applicant:
Grünenthal GmbH
Inventors:
Sven KUEHNERT, Rene Michael Koenigs, Achim Kless, Anita Wegert, Paul Ratcliffe, Ruth Jostock, Thomas Koch, Klaus Linz, Wolfgang Schroeder
Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
March 1, 2021
Publication date:
June 17, 2021
Applicant:
Grünenthal GmbH
Inventors:
Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Anita WEGERT
Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
March 1, 2021
Publication date:
June 17, 2021
Applicant:
Grünenthal GmbH
Inventors:
Sven Kuehnert, Rene Michael Koenigs, Achim Kless, Anita Wegert, Paul Ratcliffe, Ruth Jostock, Thomas Koch, Klaus Linz, Wolfgang Schroeder, Klaus Schiene, Ingo Konetzki
Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
February 9, 2021
Publication date:
June 3, 2021
Applicant:
Grünenthal GmbH
Inventors:
Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
Abstract: The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. The invention also relates to a kit comprising the contained according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in pediatric patients.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
May 25, 2021
Assignee:
Grünenthal GmbH
Inventors:
Marc Schiller, Carlos van Hemelrijck, Stefanie Straub, Eva Wulsten, Ulrike Bertram, Ulrich Reinhold
Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Grant
Filed:
July 19, 2019
Date of Patent:
April 20, 2021
Assignee:
GRÜNENTHAL GMBH
Inventors:
Florian Jakob, Jo Alen, Simon Lucas, Tobias Craan, Ingo Konetzki, Achim Kless, Stefan Schunk, Paul Ratcliffe, Sebastian Wachten, Simon Cruwys
Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.
Type:
Application
Filed:
November 2, 2020
Publication date:
February 18, 2021
Applicant:
GRÜNENTHAL GMBH
Inventors:
KLAUS WENING, SEBASTIAN SCHWIER, ULRIKE BERTRAM
Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
Type:
Grant
Filed:
August 24, 2016
Date of Patent:
February 9, 2021
Assignee:
Grünenthal GmbH
Inventors:
Nadja Gruening, Marc Schiller, Ashish Hemani, Chris Kirby, Ingo Friedrich, John Bothmer, Andreas Scholz
Abstract: The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
September 2, 2020
Publication date:
February 4, 2021
Applicant:
Grünenthal GmbH
Inventors:
Sven KUEHNERT, Rene KOENIGS, Achim KLESS, Anita WEGERT, Ingo KONETZKI, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
August 31, 2020
Publication date:
December 24, 2020
Applicant:
Grünenthal GmbH
Inventors:
Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, lngo KONETZKI